Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nCAR19-T for Recurrent/Refractory B-Cell Leukemia
NCT02644655Phase 2Unknown
- Sponsor
- Naval Medical University
- Start
- Sep 2015
- Primary completion
- Mar 2017
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of nCAR19-T in B-cell leukemia (BCL) and B-cell lymphoma (BCL), sponsored by Naval Medical University. Primary endpoint: Adverse Events at 2 years. Status: unknown.
02
Drugs
nCAR19-T
03
Conditions
B-cell leukemia (BCL)B-cell lymphoma (BCL)
Beyond the preview
Go deeper on NCT02644655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02644655.